GFAP, along with the other three non-epithelial cells belonging to the same protein family, regulates the functions and structure of the cytoskeleton. Although many studies use GFAP as a cell marker, we have still not completely understood its role in the body. The Glial fibrillary acidic protein gene encodes a type III intermediate filament protein, one of several brain proteins known collectively as GFAP. GFAP is expressed in astrocytes, glia cells that provide support and nourishment to neurons, but this protein is also found in several other cell types such as osteocytes and chondrocytes. It’s possible that this protein helps maintain the cytoskeleton in these cells.
Glial fibrillary acidic protein (GFAP) is a type III intermediate filament protein belonging to the intermediate filament protein family. The GFAP gene in humans encodes the GFAP protein. The gene is located on chromosome 17. Several CNS cell types that include ependymal cells and astrocytes express GFAP proteins during development. Other human cells, such as keratinocytes, Leydig cells, chondrocytes, and osteocytes, also express GFAP.
The Glial Fibrillary Acidic Protein (GFAP) is a type III intermediate filament protein belonging to the intermediate filament protein family. The GFAP gene in humans encodes the GFAP protein. The gene is located on chromosome 17. Several CNS cell types that include ependymal cells and astrocytes express GFAP proteins during development. Other human cells, such as keratinocytes, Leydig cells, chondrocytes, and osteocytes, also express GFAP.
PK PD study is a drug development process performed in vivo, which links drug exposure to therapeutic effect measures. It is essential to any ECTD submission as it provides investigators with comprehensive information on the relationship between exposure and efficacy of the test article. Pharmacokinetics (PK) parameters are typically calculated by non-compartmental analysis (NCA) following the determination of test article concentrations in samples from clinical or preclinical studies. Typically, area under the curve (AUC) and maximum concentration (Cmax, or C0 for an IV dose) are accepted as the most critical PK parameters when discussing exposure and activity or toxicity. AUC in pharmacokinetics represents the total exposure of the test article over the tested time course.
PK PD modeling derives estimates of the relationship between drug exposure (AUC) and therapeutic effect measures, so drug developers can better understand the relationships between exposure, efficacy, and toxicity. PK PD modeling is essential for ECTD submissions. Quantitative structure-activity relationship (QSAR) models, which describe how a molecule’s properties relate to its activity or toxicity, are based on fitting mathematical models to databases of sparse experimental data. Pharmaceuticals may be characterized by their structural components that result in specific conclusions regarding the marketed product’s therapeutic mechanisms.
PK PD software is not only useful to design and assess PK, it also provides comprehensive analysis on pharmacokinetics, pharmacodynamics, safety and efficacy to help you assess Drug Development Effort Success Rate (DDES). It also helps improve your understanding of how drug exposure influences therapeutic effect measures and can predict toxicity.
PK PD analysis is a detailed study linking drug exposure to therapeutic effect measures. Pharmacokinetic (PK) parameters are typically calculated following the determination of test article concentrations in samples from clinical or preclinical studies. One of the most critical PK parameters is AUC, or Cmax (for intravenous dose) which is accepted as the most important metric when discussing exposure and activity or toxicity. Our experts derive absolute or relative bioavailability (F%) from AUCs of multiple dose groups or administration routes.
